Amplicon files for EU trademark for its leading consumer productAmplicon, a wholly owned subsidiary of Emplicure AB (publ), that focuses on developing consumer products, today announced that it has filed at the European Union Intellectual Property Office (EUIPO) for a trademark registration for its leading product. The effective filing date was June 1, 2022. Amplicon believes that a European Union Trademark materially enhances the global value of its brand portfolio.
"We are swiftly advancing the development of our dry white nicotine pouches with unique and consumer-empowering profiles for how flavor and nicotine are released. This filing is a critical milestone because we believe that a strong brand, protected by intellectual property rights, will allow us to fully extend the value of our innovation to markets across Europe and beyond," says Tomas Hammargren, Chairman of Amplicon.
The EUIPO manages the registration of the European Union trademark (EUTM), which provides intellectual property protection in all EU Member States.
Amplicon is premiering two dry white nicotine-pouch products at the Global Forum on Nicotine in Warsaw on 16-18 June 2022. The technology springs from Amplicons IP, based on ceramic biomaterials, and represents a completely new generation of nicotine products with distinct properties for enhanced user experiences.
For more information, please contact: Torbjörn W. Larsson
CEO
Phone: +46 (0)70 747 65 99
Email: [email protected]
Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: [email protected]
Tomas Hammargren
Chairman, Amplicon AB
Phone: +46 (0) 706 494 549
Email: [email protected]
Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via [email protected]
The following documents can be retrieved from beQuoted
PM-Amplicon-files-for-EU-trademark-for-its-leading-consumer-.pdf Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. Wholly owned subisidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 